Spiral Therapeutics Announces Successful Completion of the SPT-2101 PHASE 1b/2a Clinical Trial for Meniere’s Disease, Data Presented During the 2024 AAO Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 — Spiral Therapeutics, Inc. (Spiral), a clinical-stage company focused on developing novel therapies for inner ear disorders, announced the successful completion of the Phase 1b/2a clinical trial of SPT-2101 (6% dexamethasone) in Meniere’s disease. Data review of 21 patients showed a significant reduction in vertigo frequency and severity. The study recruited […]
Spiral Therapeutics Receives Hearing Technology Innovator Award
SOUTH SAN FRANCISCO, Calif., August 30, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced today that it has been recognized for its innovative Drug Delivery Platform in the fourth annual Hearing Technology Innovator Awards™. The annual awards program by Hearing Health & Technology Matters (HHTM) acknowledges technological innovation and […]
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
SOUTH SAN FRANCISCO, Calif., March 29, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. (“Otonomy”), following the stockholder approval of Otonomy’s dissolution. The transaction includes preclinical and clinical data related to OTO-104 (OTIVIDEX), a sustained-exposure […]